Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

4(66.7%)

Phase 2

2(33.3%)

6Total

Phase 3(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00945490Phase 3Completed

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

Role: lead

NCT01846793Phase 3Completed

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

Role: lead

NCT01620515Phase 2Completed

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Role: lead

NCT01438775Phase 3Completed

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

Role: lead

NCT00918983Phase 3Completed

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

Role: lead

NCT00759135Phase 2Completed

Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)

Role: lead

All 6 trials loaded